Literature DB >> 28626076

Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block.

Robert M Clancy1, Androo J Markham2, Tanisha Jackson2, Sara E Rasmussen2, Miroslav Blumenberg2, Jill P Buyon2.   

Abstract

The signature lesion of SSA/Ro autoantibody-associated congenital heart block (CHB) is fibrosis and a macrophage infiltrate, supporting an experimental focus on cues influencing the fibroblast component. The transcriptomes of human fetal cardiac fibroblasts were analyzed using two complementary approaches. Cardiac injury conditions were simulated in vitro by incubating human fetal cardiac fibroblasts with supernatants from macrophages transfected with the SSA/Ro-associated noncoding Y ssRNA. The top 10 upregulated transcripts in the stimulated fibroblasts reflected a type I interferon (IFN) response [e.g., IFN-induced protein 44-like (IFI44L), of MX dynamin-like GTPase (MX)1, MX2, and radical S-adenosyl methionine domain containing 2 (Rsad2)]. Within the fibrotic pathway, transcript levels of endothelin-1 (EDN1), phosphodiesterase (PDE)4D, chemokine (C-X-C motif) ligand (CXCL)2, and CXCL3 were upregulated, while others, including adenomedullin, RAP guanine nucleotide exchange factor 3 (RAPGEF3), tissue inhibitor of metalloproteinase (TIMP)1, TIMP3, and dual specificity phosphatase 1, were downregulated. Agnostic Database for Annotation, Visualization and Integrated Discovery analysis revealed a significant increase in inflammatory genes, including complement C3A receptor 1 (C3AR1), F2R-like thrombin/trypsin receptor 3, and neutrophil cytosolic factor 2. In addition, stimulated fibroblasts expressed high levels of phospho-MADS box transcription enhancer factor 2 [a substrate of MAPK5 (ERK5)], which was inhibited by BIX-02189, a specific inhibitor of ERK5. Translation to human disease leveraged an unprecedented opportunity to interrogate the transcriptome of fibroblasts freshly isolated and cell sorted without stimulation from a fetal heart with CHB and a matched healthy heart. Consistent with the in vitro data, five IFN response genes were among the top 10 most highly expressed transcripts in CHB fibroblasts. In addition, the expression of matrix-related genes reflected fibrosis. These data support the novel finding that cardiac injury in CHB may occur secondary to abnormal remodeling due in part to upregulation of type 1 IFN response genes.NEW & NOTEWORTHY Congenital heart block is a rare disease of the fetal heart associated with maternal anti-Ro autoantibodies which can result in death and for survivors, lifelong pacing. This study provides in vivo and in vitro transcriptome-support that injury may be mediated by an effect of Type I Interferon on fetal fibroblasts.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  RNASeq; autoimmune congenital heart block; cardiac fibroblast

Mesh:

Substances:

Year:  2017        PMID: 28626076      PMCID: PMC5625175          DOI: 10.1152/ajpheart.00256.2017

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  55 in total

1.  Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block.

Authors:  Robert M Clancy; Anca D Askanase; Raj P Kapur; Efstathia Chiopelas; Natalie Azar; M Eugenia Miranda-Carus; Jill P Buyon
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

2.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

3.  Type I interferon system activation and association with disease manifestations in systemic sclerosis.

Authors:  Maija-Leena Eloranta; Karin Franck-Larsson; Tanja Lövgren; Sebastian Kalamajski; Anders Rönnblom; Kristofer Rubin; Gunnar V Alm; Lars Rönnblom
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

4.  High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.

Authors:  Anna R Lisney; Franziska Szelinski; Karin Reiter; Gerd R Burmester; Thomas Rose; Thomas Dörner
Journal:  Ann Rheum Dis       Date:  2017-05-13       Impact factor: 19.103

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 6.  The clinical spectrum of autoimmune congenital heart block.

Authors:  Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta
Journal:  Nat Rev Rheumatol       Date:  2015-03-24       Impact factor: 20.543

7.  ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation.

Authors:  Suji Kim; Jae Hyang Lim; Chang-Hoon Woo
Journal:  Am J Pathol       Date:  2013-10-01       Impact factor: 4.307

Review 8.  Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature.

Authors:  J M P J Breur; G H A Visser; A A Kruize; P Stoutenbeek; E J Meijboom
Journal:  Ultrasound Obstet Gynecol       Date:  2004-09       Impact factor: 7.299

9.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.

Authors:  N Hiramatsu; N Hayashi; A Kasahara; H Hagiwara; T Takehara; Y Haruna; M Naito; H Fusamoto; T Kamada
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

10.  A toll-like receptor 2 pathway regulates the Ppargc1a/b metabolic co-activators in mice with Staphylococcal aureus sepsis.

Authors:  Timothy E Sweeney; Hagir B Suliman; John W Hollingsworth; Karen E Welty-Wolf; Claude A Piantadosi
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

View more
  7 in total

1.  Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block.

Authors:  Robert M Clancy; Marc Halushka; Sara E Rasmussen; Tenzin Lhakhang; Miao Chang; Jill P Buyon
Journal:  J Immunol       Date:  2018-12-05       Impact factor: 5.422

2.  Statistical considerations in reporting cardiovascular research.

Authors:  Merry L Lindsey; Gillian A Gray; Susan K Wood; Douglas Curran-Everett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-20       Impact factor: 4.733

Review 3.  Common innate pathways to autoimmune disease.

Authors:  David Langan; Noel R Rose; Kamal D Moudgil
Journal:  Clin Immunol       Date:  2020-02-10       Impact factor: 3.969

Review 4.  What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases.

Authors:  Gabriela Riemekasten; Frank Petersen; Harald Heidecke
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

5.  In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.

Authors:  Raffaele Altara; Fouad A Zouein; Rita Dias Brandão; Saeed N Bajestani; Alessandro Cataliotti; George W Booz
Journal:  Front Cardiovasc Med       Date:  2018-02-21

6.  Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block.

Authors:  Hemant Suryawanshi; Robert Clancy; Pavel Morozov; Marc K Halushka; Jill P Buyon; Thomas Tuschl
Journal:  Cardiovasc Res       Date:  2020-07-01       Impact factor: 10.787

7.  Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero.

Authors:  Malin Hedlund; Gudny Ella Thorlacius; Margarita Ivanchenko; Vijole Ottosson; Nikolaos Kyriakidis; Linda Lagnefeldt; Joanna Tingström; Allan Sirsjö; Anders A Bengtsson; Emma Aronsson; Kristina Gemzell-Danielsson; Lars Ronnblom; Gunnar Bergman; Alexander Espinosa; Sven-Erik Sonesson; Maija-Leena Eloranta; Marie Wahren-Herlenius
Journal:  RMD Open       Date:  2020-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.